About
Nick litigates high-stakes securities and shareholder disputes, including securities fraud class actions, breach of fiduciary duty class actions, M&A disputes, and shareholder demands. He has played a leading role in arguing many novel and precedent-setting securities and shareholder issues and has been described by Legal 500 as an “emerging talent” in these areas. Nick has advised multi-national companies and their boards and management in the life sciences, automotive, technology, financial, and consumer goods sectors. He also advises on litigation avoidance and governance best practices.
VCARD
Additional Information
Nick’s recent representations include:
- AstraZeneca and its officers as alleged controlling stockholder of Viela Bio in a Delaware Court of Chancery stockholder challenge to Horizon Therapeutics’ acquisition of Viela Bio.
- Moderna and its officers and directors in a securities class action and related derivative actions alleging false statements in connection with Moderna’s RSV vaccine.
- Palantir and its officers and directors in a securities class action and related derivative actions challenging statements made in connection with Palantir’s direct listing about growth, efficiencies, revenue targets, and operations.
- Tyson Foods and its officers and directors in a securities class action and related derivative actions alleging failure to disclose purportedly insufficient COVID-19 safety protocols at Tyson facilities.
- ASML and its offers and directors in securities class action alleging false or misleading statements regarding ASML’s forecasting.
- J.P. Morgan, Barclays, Goldman Sachs, Citigroup and seven additional financial institutions in a securities class action concerning underwriting of a healthcare company’s IPO.
- BuzzFeed and its officers and directors in a Delaware Court of Chancery action seeking an anti-arbitration injunction and enforcement of BuzzFeed’s forum clause.
- CarLotz and its officers and directors in a securities class action and related derivative actions alleging failure to disclose information about CarLotz’s business model, partnerships, inventory, and unit economics.
- Acelyrin and its officers and directors in a securities class action challenging statements made in connection with Acelyrin’s IPO about its clinical trials and the potential of its lead drug candidate, Izokibep.
- Li-Cycle in securities class action challenging statements concerning Li-Cycle’s lithium-ion battery recycling methods and financial reporting.
- Society for Corporate Governance as amicus curiae before the United States Supreme Court in a securities class action concerning corporate disclosures.
Litigator of the Week Runner-Up
— The American Lawyer | April 11, 2025
Nicholas A. Caselli
Partner
T +1 212 230 4628
new york Office
3 World Trade Center
175 Greenwich Street, 51st Floor
10007 new york